Prepare for up to a Dozen Humira Biosimilars

November 2022

Up to 12 biosimilars for Humira (adalimumab) are slated to hit the market in 2023...starting with Amjevita in January.

This is a big deal. Humira is approved for several indications...rheumatoid arthritis, plaque psoriasis, Crohn’s, etc.

Plus it’s a top seller...annual revenue is over $20 billion.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Biosimilars Prepare for up to a Dozen Humira Biosimilars
Influenza Continue to Save Flu Antivirals for High-Risk Patients
Statins Clarify the Role of Statins for Primary Prevention
Contraceptives Clear Up Confusion About Emergency Contraception
Anticoagulants Know When to Rely on Warfarin Instead of a DOAC
Med Safety Watch for Gallbladder Problems in Patients on GLP-1 Agonists
Hormone Therapy Answer FAQs About Menopausal Hormone Therapy
Cardiology Match the Choice of Calcium Channel Blocker to Your Patient
Infectious Diseases Don’t Jump to Antibiotics for Acute Infectious Diarrhea
Emergency Preparedness Be Ready to Navigate Med Issues During a Disaster or Emergency